Table 1.
Outcomes in patients with cancer and COVID-19
| Alive | Deceased | |
|---|---|---|
| Total | 157 (72%) | 61 (28%) |
| Solid tumors | 123 (75%) | 41 (25%) |
| Genitourinary | 39 (85%) | 7 (15%) |
| Breast | 24 (86%) | 4 (14%) |
| Colorectal | 13 (62%) | 8 (38%) |
| Gynecologic | 8 (62%) | 5 (38%) |
| Lung | 5 (45%) | 6 (55%) |
| Head and neck | 7 (88%) | 1 (13%) |
| Neurologic | 7 (88%) | 1 (13%) |
| Upper GI | 5 (63%) | 3 (38%) |
| Hepatobiliary | 5 (71%) | 2 (29%) |
| Bone/soft tissue | 4 (80%) | 1 (20%) |
| Neuroendocrine | 3 (100%) | 0 (0%) |
| Pancreas | 1 (33%) | 2 (67%) |
| Skin | 2 (67%) | 1 (33%) |
| Hematologic malignancies | 34 (63%) | 20 (37%) |
| NHL | 10 (67%) | 5 (33%) |
| MDS | 2 (40%) | 3 (60%) |
| MPN | 5 (71%) | 2 (29%) |
| ALL | 4 (100%) | 0 (0%) |
| AML | 1 (100%) | 0 (0%) |
| MM | 8 (62%) | 5 (38%) |
| CML | 0 (0%) | 1 (100%) |
| Hodgkin lymphoma | 2 (40%) | 3 (60%) |
| CLL | 2 (67%) | 1 (33%) |
| Myeloid malignancy | 8 (57%) | 6 (43%) |
| Lymphoid malignancy | 26 (65%) | 14 (35%) |
Abbreviation: CML, chronic myeloid leukemia.